uniQure N.V. announced on June 11, 2025, the appointment of Kylie O’Keefe as Chief Customer and Strategy Officer, effective June 6, 2025. In this role, Ms. O’Keefe will be responsible for leading the development and execution of uniQure’s global commercialization strategy for AMT-130, its investigational gene therapy for Huntington’s disease.
Ms. O’Keefe brings extensive experience in rare diseases and gene therapy launches, having most recently served as Chief Commercial Officer at PTC Therapeutics. Her responsibilities at uniQure will encompass all commercial functions and medical affairs, signaling the company's intensified focus on market readiness.
This strategic hire underscores uniQure's commitment to preparing for the potential U.S. commercial launch of AMT-130 in 2026. Her expertise is expected to be invaluable as uniQure transitions towards becoming a commercial-stage biotechnology company, leveraging the clear and aligned path towards accelerated approval for AMT-130.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.